恒瑞医药
(600276)
| 流通市值：2848.22亿 | | | 总市值：2848.22亿 |
| 流通股本：63.79亿 | | | 总股本：63.79亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 20,189,303,845.1 | 13,600,734,114.77 | 5,997,533,912.14 | 22,819,784,741.31 |
| 营业收入 | 20,189,303,845.1 | 13,600,734,114.77 | 5,997,533,912.14 | 22,819,784,741.31 |
| 二、营业总成本 | 15,089,979,241.8 | 9,756,000,390.11 | 4,412,916,241.65 | 18,214,152,501.77 |
| 营业成本 | 2,833,182,677.7 | 1,873,303,655.38 | 942,849,379.52 | 3,525,247,786.91 |
| 税金及附加 | 172,414,995.14 | 114,951,556.98 | 58,017,910.82 | 219,257,133.43 |
| 销售费用 | 6,109,287,761.42 | 3,938,214,500.02 | 1,764,255,987.33 | 7,577,175,913.92 |
| 管理费用 | 1,874,111,722.11 | 1,173,998,524.87 | 576,301,558.24 | 2,416,974,460.17 |
| 研发费用 | 4,548,870,345.14 | 3,037,753,778.66 | 1,220,126,943.52 | 4,953,887,105.16 |
| 财务费用 | -447,888,259.71 | -382,221,625.8 | -148,635,537.78 | -478,389,897.82 |
| 其中:利息费用 | 3,313,597.64 | 3,314,241.63 | - | 5,903,776.07 |
| 其中:利息收入 | 490,918,277.37 | 370,788,078.84 | 166,463,087 | 477,143,415.78 |
| 加:公允价值变动收益 | 9,529,744.94 | 7,542,196.34 | 7,337,738.03 | -58,256,927.73 |
| 加:投资收益 | -31,420,370.48 | -16,140,088.65 | 615,897.07 | -49,156,803.96 |
| 资产处置收益 | 2,149,624.8 | 2,015,408.01 | 1,622,081.66 | 3,162,510.78 |
| 资产减值损失(新) | 9,250,184.59 | 15,816,450.54 | 109,562.54 | -107,216,559.21 |
| 信用减值损失(新) | -14,287,748.84 | -37,500,577.09 | -12,975,584.53 | 17,254,496.2 |
| 其他收益 | 270,744,490.42 | 168,309,001.73 | 54,681,449.36 | 498,485,970.59 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 5,345,290,528.73 | 3,984,776,115.54 | 1,636,008,814.62 | 4,909,904,926.21 |
| 加:营业外收入 | 5,790,924.24 | 3,132,564.37 | 198,808.58 | 3,798,351.9 |
| 减:营业外支出 | 264,341,297.74 | 236,308,575.04 | 133,696,788.68 | 246,593,587.87 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 5,086,740,155.23 | 3,751,600,104.87 | 1,502,510,834.52 | 4,667,109,690.24 |
| 减:所得税费用 | 470,409,977.77 | 323,467,746.83 | 135,022,146.8 | 389,288,987.74 |
| 六、净利润 | 4,616,330,177.46 | 3,428,132,358.04 | 1,367,488,687.72 | 4,277,820,702.5 |
| 持续经营净利润 | 4,616,330,177.46 | 3,428,132,358.04 | 1,367,488,687.72 | 4,277,820,702.5 |
| 归属于母公司股东的净利润 | 4,619,575,874.29 | 3,431,748,098.1 | 1,368,929,247.85 | 4,302,435,930.05 |
| 少数股东损益 | -3,245,696.83 | -3,615,740.06 | -1,440,560.13 | -24,615,227.55 |
| (一)基本每股收益 | 0.73 | 0.54 | 0.21 | 0.68 |
| (二)稀释每股收益 | 0.73 | 0.54 | 0.21 | 0.68 |
| 八、其他综合收益 | -12,630,993.15 | -17,226.74 | -5,925,391.68 | 17,841,438.93 |
| 归属于母公司股东的其他综合收益 | -11,499,309.03 | -772,837.34 | -6,141,934.94 | 16,094,142.5 |
| 九、综合收益总额 | 4,603,699,184.31 | 3,428,115,131.3 | 1,361,563,296.04 | 4,295,662,141.43 |
| 归属于母公司股东的综合收益总额 | 4,608,076,565.26 | 3,430,975,260.76 | 1,362,787,312.91 | 4,318,530,072.55 |
| 归属于少数股东的综合收益总额 | -4,377,380.95 | -2,860,129.46 | -1,224,016.87 | -22,867,931.12 |
| 公告日期 | 2024-10-25 | 2024-08-22 | 2024-04-18 | 2024-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |